Biodesix, Inc (NASDAQ:BDSX), a leader in diagnostic solutions, today announced that the American College of Chest Physicians (CHEST) has published a new framework for clinical practice, "Building a Lung Nodule Program: From Detection to Diagnosis." This groundbreaking framework describes six steps to building a comprehensive lung nodule program, with validated biomarker testing, such as the Biodesix Nodify Lung® tests, as a core component of standardizing risk stratification to guide clinical decisions.

The new CHEST framework was developed by a multidisciplinary panel of nationally recognized interventional pulmonologists, thoracic surgeons, and diagnostic radiologists representing leading hospitals and health systems throughout the United States. Drawing on published clinical evidence and real-world experience from established lung nodule programs, the panel defines a practical roadmap for building high performing programs that deliver consistent, evidence-based care and improve outcomes for patients with pulmonary nodules.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.